EMVision Medical Devices (EMV) Q1 2026 TU earnings summary

Executive summary

• Recruitment accelerated in the Pivotal (Validation) Trial for the emu™ device, supporting regulatory submission and market entry.

• Continuous Innovation Study provided ongoing insights for AI algorithm training and feature development.

• First Responder device advanced with ethics approval for key studies and initial deployments in emergency settings.

• Received a $3 million CRC-P grant to evaluate expedited stroke care in regional hospitals.

• Raised $12 million via placement, with additional $2 million from an oversubscribed Share Purchase Plan.

Financial highlights

• Cash reserves stood at $18.35 million as of 30 September 2025.

• Net operating cash outflows for the quarter were $3.487 million, including $1.298 million in R&D, $1.803 million in staff costs, and $0.737 million in corporate administration.

• Received $400,000 milestone payment under the Australian Stroke Alliance grant.

• Additional $7.4 million in non-dilutive funding available from current grant programs.

Outlook and guidance

• Focus remains on accelerating patient recruitment, advancing First Responder studies, and preparing for regional benefits study.

• Participation in major industry events and building go-to-market strategy.

• Funds raised to support FDA submission, commercialisation, and clinical milestones through FY26 and FY27.